Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ahmad Rifai

Internal Medicine Panama City, FL Medical Doctor

NPI 1396741526 CMS profile 154133

615 N Bonita Ave, Panama City, FL 32401

Open in the dashboard

General payments

$66,468

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ahmad Rifai of Panama City, FL is reported in the CMS Open Payments database as having received $66,468 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $361 10
2024 General $5,896 20
2023 General $1,274 23
2022 General $7,339 25
2021 General $16,110 28
2020 General $12,309 19
2019 General $23,180 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmad Rifai
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ahmad Rifai were reported at $361. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ahmad Rifai Internal Medicine median Middle half National median
2019 $23,180 $159 $48–$570 $163
2020 $12,309 $119 $33–$402 $114
2021 $16,110 $135 $37–$521 $132
2022 $7,339 $141 $42–$496 $149
2023 $1,274 $149 $45–$519 $160
2024 $5,896 $154 $47–$537 $164
2025 $361 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relypsa, Inc. $54,795 101 payments
  2. Fresenius USA Marketing, Inc. $6,080 18 payments
  3. Otsuka America Pharmaceutical, Inc. $3,503 14 payments
  4. Aurinia Pharma U.S., Inc. $686 11 payments
  5. AstraZeneca Pharmaceuticals LP $191 5 payments
  6. Inari Medical, Inc. $144 1 payment
  7. Abiomed $137 1 payment
  8. Bayer HealthCare Pharmaceuticals Inc. $117 2 payments
  9. Melinta Therapeutics, Inc. $115 1 payment
  10. Horizon Therapeutics plc $103 1 payment
  11. Other $596 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,026 31 payments
  2. Travel and Lodging $10,252 36 payments
  3. Food and Beverage $4,573 94 payments
  4. Honoraria $4,500 3 payments
  5. Education $118 16 payments
Products named General payments · program years 2019–2025
  1. Veltassa Hyperkalemia $31,893 58 payments
  2. Veltassa Hyperkalemia $22,841 41 payments
  3. Velphoro $5,917 15 payments
  4. JYNARQUE $2,378 4 payments
  5. SAMSCA $1,122 10 payments
  6. LUPKYNIS $686 11 payments
  7. FARXIGA $171 4 payments
  8. CT THROMBECTOMY SYSTEM KIT $144 1 payment
  9. FLOWTRIEVER CATHETER, S $144 1 payment
  10. Korsuva $122 2 payments
  11. Other $985 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

45

Median for Internal Medicine: 777

Drug cost

$134

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Losartan Potassium Generic 17 $73
Carvedilol Generic 16 $43
Furosemide Generic 12 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$156,029

Medicare's payments for the services billed

Medicare patients

317

Average age 74

Services billed

2,870

134 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Heart failure 71%
Diabetes 69%
Ischemic heart disease 64%
Arthritis 62%
Atrial fibrillation 54%
COPD 49%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Velphoro
  • Fresenius USA Marketing, Inc. $5,667
$5,667 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $153
$153 — —
CARNITOR
  • Leadiant Biosciences, Inc. $27
$27 — —
IBSRELA
  • Ardelyx, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record